lines for initiating HAART that include a protease inhibitor in combination with nucleoside and non-nucleoside reverse transcriptase inhibitors. 4~
Prior to the introduction of HAART, treatment options for HIV had limited impact, and the primary clinical strategies used were palliative. These medications have had a dramatic and profound effect in reducing HIV viral load and improving the clinical and immunologic course of patients in randomized trials and clinical settings, even those patients with advanced HW/AIDS. 6-12 Although these therapies do not constitute a cure, survival has been lengthened, as noted in clinical studies 13-17 and in broad-based population analyses in New York City is and the US overall. 19~~
These rapid and dramatic changes in H1V therapeutics have resulted in some persons living with HW/AIDS being able to return to active, high-functioning lives for long periods of time. For others, decreased mortality rates have resulted in the emergence of a new, more prolonged chronic disease phase of the illness marked by progressive disability and significant comorbidities. This chronic disease phase--in effect, the conversion of death to disability--takes place over a potentially protracted time course, with exacerbations and remissions resembling other chronic diseases, unlike the more stereotypic and rapidly fatal course of HIV disease so familiar earlier in the epidemic prior to the advent of HAART.
For such patients, the trends in improved survival will result in greater need for long-term care, including institutional care, with the likelihood that long-term care facilities will occupy an important and increasingly strategic role in the continuum of care services for AIDS patients. Such facilities will continue to be sites where patients with late-stage disease and disability will receive palliative, symptom-oriented care, as well as more disease-specific interventions as medical treatment for HIV continues to evolve.
In addition, while the cited changes in treatment have lengthened overall survival significantly, for some patients the treatment fails or is no longer effective due to factors such as development of viral resistance or nonadherence to treatment regimens as a result of toxicity or side effects. While there have been reports of substantial decreases in deaths, most likely due to HAART, recent observations in New York City of increasing deaths and nationwide decreases in mortality allude to a gradual reversal of this trend (M. A. Chiasson, personal communication, September 1999), suggesting further that these therapies are not curative, and that end-of-life issues remain salient. This review addresses some of the clinical issues now facing HW caregivers in the new therapeutic era, specifically with respect to late-stage disease, long-term care, and palliative and end-of-life care. ET AL. Data suggest that the specific symptoms that predominate during the terminally ill phase may shift as the patient approaches death. Shortly before death (10 weeks), gastrointestinal and constitutional symptoms were the most frequent, and at the time of death, cough and breathlessness were the most common. 27 In a symptom profile study of terminally ill ambulatory and hospitalized AIDS patients who died before 1995, the most frequent symptoms 3 months prior to death were anorexia (63%), fatigue (60%), and pain (60%); at the time of death, the most frequent symptoms were fever (82%), fatigue (70%), and dyspnea (68%).2s
PALLIATIVE CARE AND HIV
It is possible that, with many patients experiencing lengthened survival during the era of HAART, the predominant symptoms will be peripheral neuropathy, Limited data suggest that the spectrum of symptoms may be distinct for men and women: Men report experiencing more neuropathic pain and visual loss, while women report experiencing more headache and musculoskeletal pain and lower respiratory tract symptoms, especially among injection drug users (IDUs). z2
Fatigue has also been reported more frequently by women than men and more commonly reported among patients who reported heterosexual or injection drug use compared to those with homosexual high-risk transmission behavior. 39 An 
